Validation of a lateral flow immunoassay for the detection of immunoglobulin G/immunoglobulin M antibodies to severe acute respiratory syndrome coronavirus 2-COVID-19 among symptomatic and asymptomatic high-risk OBGYN patients in selected hospitals in Olongapo city and Zambales – A multicenter prospective study

2021 ◽  
Vol 45 (1) ◽  
pp. 23
Author(s):  
MadonnaM Valenzuela ◽  
ToscaCamille S. Guiao ◽  
CorazonR Valdez ◽  
LouellaP Aquino ◽  
DaisyGrace Z. Rivera
Keyword(s):  
High Risk ◽  
Severe Acute Respiratory Syndrome ◽  
Prospective Study ◽  
Immunoglobulin G ◽  
Lateral Flow ◽  
Immunoglobulin M ◽  
Lateral Flow Immunoassay ◽  
Multicenter Prospective Study

scholarly journals Seroprevalence of Severe Acute Respiratory Syndrome-Coronavirus-2 Immunoglobulin M and Immunoglobulin G Antibodies among the Population of Koya University

2021 ◽  
Vol 9 (2) ◽  
pp. 51-57
Author(s):  
Safia S. I. Blbas ◽  
Hiwa A. Ahmad ◽  
Dawan J. Hawezy ◽  
Hemn Shawgery ◽  
Hersh N. Bahadin
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Infection Rate ◽  
Immunoglobulin G ◽  
Prevalence Rate ◽  
Complete Blood Count ◽  
Immunoglobulin M ◽  
Teaching Staff ◽  
Serological Detection ◽  
Population Total ◽  
Elisa Technique

Coronavirus is a pandemic disease. In most cases, the exact infection rate cannot be determined as not everybody can be tested for the virus, even though some of them carry the virus silently. Therefore, detection of antibodies of this virus is more practical to give us a better clue about the rate of infection because the asymptomatic people can be tested too. The serological detection of anti-Severe Acute Respiratory Syndrome-Coronavirus (SARS-COV-2) antibodies among asymptomatic and moderate symptomatic individuals gives us the vital point to understanding the prevalence rate of COVID-19 among the population. Total of (436) volunteers were participated, (96) from teaching staff, (172) employee, and (168) students. Anti-SARS-COV-2 immunoglobulin G (IgG) and Immunoglobulin M (IgM) were detected in the serum by ELISA technique, and complete blood count was performed for all participants. The number of seropositive of anti-SARS-COV-2/IgG was (159), whereas IgM was (66). The highest prevalence rate of IgG detected among participants with family member infected with coronavirus (42.7%). Total WBCs count significantly increased among IgM positive participants. Many asymptomatic people were infected with coronavirus, which lead to more spreading of the virus among the population. Therefore, mass screening of the population for specific antibody against coronavirus is important to reduce the infection rate.

scholarly journals Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses

2020 ◽  
Author(s):  
Yaniv Lustig ◽  
Shlomit Keler ◽  
Rachel Kolodny ◽  
Nir Ben-Tal ◽  
Danit Atias-Varon ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Envelope Protein ◽  
False Positive ◽  
In Silico ◽  
Rapid Test ◽  
Cross Reactivity ◽  
Lateral Flow ◽  
Immunoglobulin M ◽  
Enzyme Linked Immunosorbent Assay ◽  
Elisa Testing

Abstract Background Coronavirus disease 2019 (COVID-19) and dengue fever are difficult to distinguish given shared clinical and laboratory features. Failing to consider COVID-19 due to false-positive dengue serology can have serious implications. We aimed to assess this possible cross-reactivity. Methods We analyzed clinical data and serum samples from 55 individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To assess dengue serology status, we used dengue-specific antibodies by means of lateral-flow rapid test, as well as enzyme-linked immunosorbent assay (ELISA). Additionally, we tested SARS-CoV-2 serology status in patients with dengue and performed in-silico protein structural analysis to identify epitope similarities. Results Using the dengue lateral-flow rapid test we detected 12 positive cases out of the 55 (21.8%) COVID-19 patients versus zero positive cases in a control group of 70 healthy individuals (P = 2.5E−5). This includes 9 cases of positive immunoglobulin M (IgM), 2 cases of positive immunoglobulin G (IgG), and 1 case of positive IgM as well as IgG antibodies. ELISA testing for dengue was positive in 2 additional subjects using envelope protein directed antibodies. Out of 95 samples obtained from patients diagnosed with dengue before September 2019, SARS-CoV-2 serology targeting the S protein was positive/equivocal in 21 (22%) (16 IgA, 5 IgG) versus 4 positives/equivocal in 102 controls (4%) (P = 1.6E−4). Subsequent in-silico analysis revealed possible similarities between SARS-CoV-2 epitopes in the HR2 domain of the spike protein and the dengue envelope protein. Conclusions Our findings support possible cross-reactivity between dengue virus and SARS-CoV-2, which can lead to false-positive dengue serology among COVID-19 patients and vice versa. This can have serious consequences for both patient care and public health.

Sentinel Node Biopsy in 105 High-Risk Cutaneous SCCs of the Head and Neck: Results of a Multicenter Prospective Study

2019 ◽  
Vol 26 (13) ◽  
pp. 4481-4488 ◽  
Author(s):  
Craig P. Mooney ◽  
Richard C. W. Martin ◽  
Richard Dirven ◽  
Bruce G. Ashford ◽  
Kerwin Shannon ◽  
...  
Keyword(s):  
High Risk ◽  
Prospective Study ◽  
Sentinel Node ◽  
Head And Neck ◽  
Sentinel Node Biopsy ◽  
Node Biopsy ◽  
Multicenter Prospective Study

scholarly journals Performance of Commercially Available Rapid Serological Assays for The Detection of SARS-CoV-2 Antibodies

2020 ◽  
Author(s):  
Anwar M Hashem ◽  
Rowa Y Y Rowa Y Alhabbab ◽  
Abdullah Algaissi ◽  
Mohamed A Alfaleh ◽  
Sharif Hala ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Significant Variation ◽  
High Specificity ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Specific Antibodies ◽  
Time Points ◽  
Igm Antibodies ◽  
Specific Igg ◽  
High Degree

Abstract Background: The Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally. Although several commercial SARS-CoV-2 rapid serological assays have been developed, little is known about their performance and accuracy in detecting SARS-CoV-2 specific antibodies in COVID-19 patient samples. Method: We have evaluated the performance of seven commercially available rapid lateral flow immunoassay (LFIA) serological assays obtained from different manufacturers, and compared them to in-house developed and validated ELISA assays for the detection of SARS-CoV-2 specific IgG and IgM antibodies in COVID-19 patients. Results: While all evaluated LFIA assays showed high specificity, our data showed a significant variation in sensitivity of these assays in which it ranged from 0 to 54% for samples collected early during infection (3-7 days post symptoms onset) and from 54 to 88% for samples collected at later time points during infection (8-27 days post symptoms onset). Conclusion: Commercially available LFIA assays for detection of SARS-CoV-2 specific antibodies may be specific and show high degree of variation in their sensitivity. Further evaluations and validation of rapid serological assays is needed before being routinely used in detecting IgM and IgG in COVID-19 patients.

scholarly journals Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study

Blood ◽  
2015 ◽  
Vol 125 (25) ◽  
pp. 3956-3962 ◽  
Author(s):  
Yu Wang ◽  
Qi-Fa Liu ◽  
Lan-Ping Xu ◽  
Kai-Yan Liu ◽  
Xiao-Hui Zhang ◽  
...  
Keyword(s):  
High Risk ◽  
Prospective Study ◽  
Key Points ◽  
First Remission ◽  
Multicenter Prospective Study

Key Points Haploidentical transplant achieves outcomes similar to those of identical-sibling transplant for AML patients in first remission. Haploidentical transplant is a valid postremission treatment of intermediate- or high-risk AML patients lacking an identical donor.

scholarly journals Evaluation of the card test for diagnosis of human brucellosis

1978 ◽  
Vol 7 (5) ◽  
pp. 454-458
Author(s):  
A O Russell ◽  
C M Patton ◽  
A F Kaufmann
Keyword(s):  
High Risk ◽  
Immunoglobulin G ◽  
Agglutination Test ◽  
Immunoglobulin M ◽  
Serological Diagnosis ◽  
Human Brucellosis ◽  
Relative Efficacy ◽  
Potential Exposure ◽  
High Risk Populations ◽  
Card Test

The relative efficacy of the card test in the diagnosis of human brucellosis was evaluated by comparison with four other tests: the standard tube agglutination test, centrifugation agglutination test, 2-mercaptoethanol degradation technique, and 2-mercaptoethanol centrifugation agglutination test. A total of 1,701 serum specimens from persons with various degrees of potential exposure to brucella organisms or cross-reactive antigens were used in this study. In comparison with standard tube agglutination results, the card test had a sensitivity of 95.3% and a specificity of 84.1%. The card-test antigen was nonreactive with serum specimens from tularemia patients and cholera vaccinees. Our data indicated that this test measures both immunoglobulin G and immunoglobulin M agglutinins. The value of the card test in the presumptive serological diagnosis of clinical brucellosis in humans appears to be low; however, the card test may be of value in serological surveys to delineate high-risk populations.

scholarly journals Diagnostic indexes of a rapid immunoglobulin G/immunoglobulin M combined antibody test for severe acute respiratory syndrome coronavirus 2

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ying Liu ◽  
Yue-Ping Liu ◽  
Bo Diao ◽  
Jin-Ya Ding ◽  
Meng-Xue Yuan ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Immunoglobulin G ◽  
Antibody Test ◽  
Immunoglobulin M
Sign in / Sign up

Export Citation Format

Share Document